Update of the BIG 1-98 Trial: Where do we stand?

Breast

Volumn 18, Issue SUPPL.3, 2009, Pages

  Joerger, Markus ^a   Thürlimann, Beat ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

Author keywords

Adjuvant treatment; Aromatase inhibitor; Breast cancer; Endocrine therapy; Letrozole; Tamoxifen

Indexed keywords

LETROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION; TREND STUDY; UNSPECIFIED SIDE EFFECT;

EID: 68949189914     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(09)70278-4     Document Type: Article

References (25)

1. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 9 (2003 Nov 1) 1802-1810
2. Boccardo F., Rubagotti A., Puntoni M., Guglielmini P., Amoroso D., Fini A., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 23 22 (2005 Aug 1) 5138-5147
3. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004 Mar 11) 1081-1092
4. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 17 (2005 Sep 7) 1262-1271
5. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 9484 (2005 Aug 6) 455-462
6. Thürlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 26 (2005 Dec 29) 2747-2757
7. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 9324 (2002 Jun 22) 2131-2139
8. Winer E.P., Hudis C., Burstein H.J., Wolff A.C., Pritchard K.I., Ingle J.N., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23 3 (2005 Jan 20) 619-629
9. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 7 (2007 Jul) 1133-1144
10. Carlson R.W., Brown E., Burstein H.J., Gradishar W.J., Hudis C.A., Loprinzi C., et al. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw 4 Suppl 1 (2006 Mar) S1-26
11. Coates A.S., Keshaviah A., Thurlimann B., Mouridsen H., Mauriac L., Forbes J.F., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 5 (2007 Feb 10) 486-492
12. Viale G., Giobbie-Hurder A., Regan M.M., Coates A.S., Mastropasqua M.G., Dell'Orto P., et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 26 34 (2008 Dec 1) 5569-5575
13. Crivellari D., Sun Z., Coates A.S., Price K.N., Thurlimann B., Mouridsen H., et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26 12 (2008 Apr 20) 1972-1979
14. Rasmussen B.B., Regan M.M., Lykkesfeldt A.E., Dell'Orto P., Del C.B., Henriksen K.L., et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9 1 (2008 Jan) 23-28
15. Mauriac L., Keshaviah A., Debled M., Mouridsen H., Forbes J.F., Thurlimann B., et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18 5 (2007 May) 859-867
16. Mouridsen H., Keshaviah A., Coates A.S., Rabaglio M., Castiglione-Gertsch M., Sun Z., et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 25 36 (2007 Dec 20) 5715-5722
17. Viale G., Giobbie-Hurder A., Regan M.M., Coates A.S., Mastropasqua M.G., Dell'Orto P., et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 26 34 (2008 Dec 1) 5569-5575
18. Ruhstaller T., von M.R., Rufibach K., Ribi K., Glaus A., Spaeti B., et al. Breast cancer patients on endocrine therapy reveal more symptoms when self-reporting than in pivotal trials: an outcome research study. Oncology 76 2 (2009) 142-148
19. Hadji P., Ziller M., Kieback D.G., Dornoff W., Tessen H.W., Menschik T., et al. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol (2009 Feb 13) [Epub ahead of print].
20. Kaufmann M., Jonat W., Hilfrich J., Eidtmann H., Gademann G., Zuna I., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 25 19 (2007 Jul 1) 2664-2670
21. Cuzick J., Sasieni P., and Howell A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?. Br J Cancer 94 4 (2006 Feb 27) 460-464
22. Reid D.M., Doughty J., Eastell R., Heys S.D., Howell A., McCloskey E.V., et al. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34 Suppl 1 (2008) S3-18
23. Brufsky A.M. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors. Clin Breast Cancer 8 Suppl 1 (2007 Dec) S22-S34
24. Aapro M., Abrahamsson P.A., Body J.J., Coleman R.E., Colomer R., Costa L., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 19 3 (2008 Mar) 420-432
25. Hillner B.E., Ingle J.N., Chlebowski R.T., Gralow J., Yee G.C., Janjan N.A., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21 21 (2003 Nov 1) 4042-4057